In elderly patients with suspected prostate cancer, PSMA PET/CT can diagnose advanced disease and aid in therapy selection without the need for a biopsy. Published in the July issue of The Journal of ...
The MarketWatch News Department was not involved in the creation of this content. Precede Biosciences Presents New Data at ESMO 2024 Demonstrating Ability to Reveal Tumor PSMA Expression from a Simple ...
BOSTON, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Precede Biosciences, a company impacting the development and use of precision medicines with a first-in-class comprehensive epigenomic liquid biopsy platform, ...
New research presented at the 2025 International Kidney Cancer Symposium found that patients with localized renal cell carcinoma (RCC) who maintained a BMI of 35 or higher after diagnosis had improved ...
Prostate-specific membrane antigen (PSMA) is a leading target for next-generation prostate cancer therapies, with one FDA-approved medicine and 30 medicines in development Quantitative PSMA-PET ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback